Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

September 5, 2023

Primary Completion Date

January 21, 2025

Study Completion Date

June 30, 2025

Conditions
Non-Alcoholic Fatty Liver DiseaseNonalcoholic SteatohepatitisFatty Liver
Interventions
DRUG

HU6

HU6 is being evaluated for its efficacy in improving liver fat content in subjects with Nonalcoholic Steatohepatitis (NASH)

OTHER

Placebo

Placebo

Trial Locations (20)

33014

Panax Clinical Research, Miami Lakes

33155

Miami Clinical Research, Miami

33156

Advanced Clinical Research, Miami

33173

Century Research, LLC, Miami

33176

Entrust Clinical Research, Miami

33907

Southwest General Healthcare Center, Fort Myers

33914

ABMED Clinical Research Corp., Cape Coral

34208

Synergy Healthcare, Bradenton

58104

Lillestol Research, Fargo

70072

Tandem Clinical Research, Marrero

77030

Mt Olympus Medical Research, Houston

77079

Houston Research Institute, Houston

78215

Texas Liver Institute, San Antonio

78745

IMA Clinical Research-Austin, Austin

90057

Velocity Clinical Research, Los Angeles

91763

Catalina Research Institute, Montclair

91911

ProSciento CRU, Chula Vista

92404

Metro Clinical Trials, San Bernardino

95821

Northern California Research Center, Sacramento

08009

CenExel HRI, Berlin

All Listed Sponsors
lead

Rivus Pharmaceuticals, Inc.

INDUSTRY

NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis | Biotech Hunter | Biotech Hunter